Medical Xpress on MSN: Global trial shows targeted heart drug reduces obstructive hypertrophic cardiomyopathy in youth Global trial shows targeted heart drug reduces obstructive hypertrophic cardiomyopathy in youth The FDA on Friday approved aficamten (Myqorzo) for symptomatic obstructive hypertrophic cardiomyopathy (HCM), drugmaker Cytokinetics announced. Aficamten is an allosteric and reversible inhibitor of ... Medical Xpress on MSN: Mavacamten improves obstruction in adolescents with hypertrophic cardiomyopathy Adolescent patients with obstructive hypertrophic cardiomyopathy (HCM) who received the drug mavacamten saw a significant improvement in left ventricular outflow tract (LVOT) gradient, a measure of ...
WebMD: FDA Approves Myqorzo, a New Oral Therapy for Obstructive Hypertrophic Cardiomyopathy What Is Myqorzo, and Why Does It Matter? Myqorzo (aficamten) is a new oral medicine approved by the FDA for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). It relieves symptoms ... The American Journal of Managed Care: FDA Approves Aficamten for Obstructive Hypertrophic Cardiomyopathy
